{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-171145","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2023-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.998843+00:00","generated_at":"2026-06-13T20:05:30.587218+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Prelude Therapeutics shareholders elect two Class III directors, ratify auditor, approve charter amendment","bullets":["Krishna Vaddi, Ph.D. and Mardi C. Dier elected as Class III directors with ~27M votes for each.","Ernst & Young LLP ratified as independent auditor for FY2023 with 28.78M for, 6,022 against.","Amendment to certificate of incorporation for officer exculpation passed with 22.71M for, 97,553 against.","All proposals passed; broker non-votes reported for director elections and charter amendment."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-171145","json":"https://secwatch.observer/filing/0001193125-23-171145.json","markdown":"https://secwatch.observer/filing/0001193125-23-171145.md","text":"https://secwatch.observer/filing/0001193125-23-171145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000119312523171145/0001193125-23-171145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000119312523171145/d453914d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T20:05:30.587218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24902db49ee47e6e3930bcb3e173c15c2b88f65e","claim":"Prelude Therapeutics Inc shareholders approved Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023 at the 2023-06-16 meeting.","evidence_excerpt":"Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312523171145/0001193125-23-171145-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"d52b721aa28b9c9f1e297267d3fc23f4a9ed1060","claim":"Prelude Therapeutics Inc shareholders approved Approval of an amendment to the Company's Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation at the 2023-06-16 meeting.","evidence_excerpt":"Approval of an amendment to the Company's Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312523171145/0001193125-23-171145-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"},{"claim_id":"ecee93aa86613c867550abd14c73180dda20c5c5","claim":"Prelude Therapeutics Inc shareholders approved Election of two Class III Directors, Krishna Vaddi, Ph.D., and Mardi C. Dier at the 2023-06-16 meeting.","evidence_excerpt":"Election of two Class III Directors, Krishna Vaddi, Ph.D., and Mardi C. Dier, each to serve a three-year term, which will expire at the 2026 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director's earlier resignation or removal.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000119312523171145/0001193125-23-171145-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-16"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}